Paired samples of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and the subsequent diffuse large cell lymphoma (DLL) of six cases of Richter's syndrome were investigated to establish the clonal relationship between the CLL/SLL and the DLL components and to define the oncogene and/or tumor-suppressor gene alterations involved in the morphologic transformation of CLL/SLL. Southern blot hybridization analysis showed identical clonal immunoglobulin (lg) gene-rearrangement patterns in the CLL/SLL and DLL components in four cases and different lg gene-rearrangement patterns in two cases. Polymerase chain reaction (PCR) amplification, cloning, and DNA sequencing of complementary determinant region 3 (CDR3) of the 19-heavy chain gene of one of the two cases in which the lg gene-rearrangement patterns were different showed nonidentical sequences in the CLL/SLL and DLL components. In the other case, monomorphic Epstein-Barr virus (EBV) genome integration was detected in the DLL but not in the CLL, suggesting that the CLL and DLL components in this case of Richter's syndrome also represent unrelated clones. Single-strand conformation polymorphism (SSCP) analysis and sequencing of exons 5
However, despite the well-known occurrence of this phenomenon, the precise clonal relationship between the two neoplastic cell populations is still unclear. It has been suggested, based on immunohistologic, immunoglobulin (Ig) isotype, anti-idiotype, Ig gene rearrangement and cytogenetic studies, that the DLL develops as a clonal evolution from CLL/SLL?I5 or alternatively, that the two neoplasms are distinct, unrelated clonal proliferations.16-20 Unfortunately, a definitive conclusion can not be drawn from these conflicting reports.21*22 In fact, there are many potential explanations for these disparate results. For example, different cases have been evaluated by different methods, each of which possess their own limitations. Furthermore, somatic point mutation:'-24 isotype switching and postrearrangement gene deletion12 of the Ig genes may be responsible for observed differences in Southern blot analyses and different reactivities of anti-idiotype antibodies.
Oncogene activation and tumor-suppressor gene mutation are not known to occur in the majority of cases of CLL/ SLL,25 although bcl-l and bcl-2 rearrangements and p53 gene mutations have been reported in sporadic cases. 26 In contrast, elevated c-myc oncogene expression:' retinoblastoma (Rb) gene deletion,28 and p53 tumor-suppressor gene m u t a t i~n~~.~~ have been reported in some cases ofCLL/SLL showing clinical progression and morphologic transformation. These findings suggest that certain specific genetic through 9 of the p53 tumor-suppressor gene showed a mutation in codon 1 76 of the DLL but not in the CLLJSLL component in one case where the CLL/SLL and C)LL represented different clones. The p53 mutation probably played a role in the development of the lymphoma rather than morphologic transformation of the CLL/SLL in this case. SSCP analysis and sequencing also showed identical mutations in codon 282 in both the CLL/SLL and DLL comWnents in a case where the CLL and DLL represented identiual clones. Thus, this p53 gene mutation was present both before and after morphologic transformation, and therefore, probably did not play a primary role in this process. Southern blot hybridization analysis failed to show evidence of bcl-l , bcl-2, c-myc proto-oncogene or retinoblastoma (Rb) tumorsuppressor gene rearrangements in these six cases of Richter's syndrome. In conclusion, the original CLL/SLL and the subsequent DLL in Richter's syndrome may or may not be derived from identical clones, and the well-known proto-oncogenes and tumor-suppressor genes do not appear to play an obvious and consistent role in the morphologic transformation of CLL/SLL to DLL. events may play a role in this transformation. However, comparative studies of structural alterations of oncogenes and tumor-suppressor genes in both the CLL/SLL and the DLL components occumng in the same patient have not been performed.
For these reasons, we sought to determine the clonal relationship between the original CLL/SLL and the subsequent DLL in Richter's syndrome and identify the oncogenes and tumor-suppressor genes that are involved in morphologic transformation and tumor progression. We investigated six cases of Richter's syndrome in which both the CLL/SLL and the DLL components in each case were available for analysis. Using a variety of molecular genetic approaches we were able to show that Richter's syndrome may occur through different pathways, ie, the DLL may be clonally related to or clonally distinct from the original CLL/SLL, and that specific oncogene or tumor-suppressor gene alterations do not appear to characterize the morphologic transformation and clinical progression of CLL/SLL to DLL.
MATERIALS AND METHODS
Patients and pathologic samples. Six cases of Richter's syndrome were included in this report based strictly upon the availability of sufficient quantities of fresh pathologic specimens of both the CLL/SLL and DLL components to perform the studies described below. Heparinized peripheral blood (PB) samples and lymph node biopsy specimens were collected during the course of routine clinical evaluation using standard diagnostic procedures and promptly delivered to the laboratory. Mononuclear cells were separated from the PB and lymph node samples by Ficoll-Hypaque (Pharmacia Fine Chemicals, Piscataway, NJ) density gradient centrifugation. The mononuclear cells were cryopreserved in a viable state in fetal calf serum and dimethylsulfoxide at -170°C until needed. Representative hematoxylin-and eosin-stained sections were prepared from portions of each lymph node biopsy that was routinely fixed in buffered formalin, B5, or Bouin's and embedded in paraffin. Representative portions of each tissue specimen were embedded in a cryopreservativesolution (OCT compound, Miles, Elkhart, ID) and stored at -70°C. The diagnosis of Richter's syndrome was based upon correlative analysis of the clinical, morphologic, and immunophenotypic characteristics.
Immunophenotypic characterization. The immunophenotypic profiles of the CLL/SLLs and DLLs was determined at the time of diagnosis by immunohistochemical staining of frozen or paraffin tissue sections using a three step avidin-biotin immunoperoxidase technique or an immunoalkaline phosphatase antialkaline phosphatase method, and/or by direct and indirect immunofluorescent flow cytometry of isolated cells in suspension using the FACScan fluorescent activated cell sorter (Becton Dickinson, Mountain View, CA) in conjunction with a large panel of polyclonal and monoclonal antibodies (MoAbs) as previously de~cribed.~' DNA extraction. Genomic DNA was extracted from cryopreserved mononuclear cell suspensions and tissue blocks using a salting-out procedure.32 Briefly, the cells or frozen tissue sections were resuspended in 3 mL of nuclei lysis buffer containing I O mmol TrisHCI, 400 mmol NaCI, and 2 mmol EDTA; 200 pL of 10% sodium dodecyl sulfate (SDS) and 500 p L of proteinase K solution ( l mg proteinase K in I% SDS and 2 mmol EDTA) were subsequently added. After overnight digestion at 37"C, I mL of saturated NaCl was added. This mixture was centrifuged at 2,500 rpm for 20 minutes, and 2 volumes of ethanol were added to the supernatant to precipitate the DNA, which was washed several times in 70% ethanol.
Sotrfhern blot analysis. Five-microgram aliquots of genomic DNA were digested with the appropriate restriction endonucleases according to the manufacturer's instructions (Boehringer-Mannheim, Indianapolis, IN), electrophoresed in 0.8 or I % agarose gels, denatured with alkali, neutralized, and transferred to nitrocellulose filters (Schleicher & Schuell, Keene, NH)." The filters were hybridized in 50% formamide/3X standard-citrate (SSC) buffer at 37'C to DNA probes that had been 3zP-labeled by the random-primer extension method and to synthetic oligonucleotide probes that had been 5'end labeled with "P using direct T4 kinase phosphorylation according to the manufacturer's instructions (Boehringer-Mannheim). The filters were washed in 0.2X SSC/0.5% SDS at 60°C for 2 hours and then autoradiographed at -70°C for 16 to 48 hours as previously described.34 DNA and synthetic oligonucleotide probes. The Ig heavy chain gene was investigated by hybridization of EcoRI and Hind111 digested DNAs to an Ig heavy chain joining region probe (JH). 35 The Ig light chain genes were studied by hybridization of EcoRI and BurnHI digested DNAs to an Ig-K light chain joining region probe ( J K )~ and an Ig-h light chain constant region probe (CA), respecti~ely.~' The T-cell receptor 0 chain (TB) gene was investigated by hybridization of BarnHI-digested DNAs to the TB gene-constant region probe.38 The organization of the c-myc locus was analyzed by hybridization of EcoRI-and HindIII-digested DNAs to the MC4 1 3RC probe. 39 The hcl-1 locus of chromosome I 1 was investigated by hybridization of Hind111 and EcoRI digests of DNA to the 2. l-kb Sac I fragment for the major translocation cluster (MTC) breakpoint and 460-bp Pvu 11-Smu 1 genomic fragment designated p94PS that lies approximately 23.4-kb of the MTC.40 The bcl-2 locus was investigated by hybridization of BamHI-digested DNAs to the pFL-l and pFL-2 probes representing a portion of chromosome 18 at the major and minor bcl-2 breakpoint regions, respect i~e l y .~' ,~~
The Rbl locus was analyzed by hybridization ofHindI11-digested DNAs using 5'-Rb (0.7-kb, Hpa I-EcoRI) and 3"Rb (3.9-kb, EcoRI-EcoRI) subclones derived from the full-length Rbl cDNA (gift of S. Friend, Harvard Medical School, Charlestown, MA)43 corresponding to exons 1 to 9 and IO to 27, respectively. The Epstein-Barr virus (EBV) genome was detected by hybridization of BamHI-digested DNAs to the 5.2-kb BarnHI-EcuRI fragment of EBV genomic termini.44 Two highly polymorphic markers for loci onchromosome 17,pYNZ22.145andp144-D646wereusedtoassess the loss of heterozygocity in the p53 mutated case, as well as to evaluate the possibility of p53 deletion in the nonmutated cases. The nitrocellulose filter of the EcoRI-digested DNAs of case number two, which was probed with JH, was rehybridized with case-specific CDR3 synthetic oligonucleotides (ACCCACCTC TTGGGTACGGATGACCTCCCGGGGAGGCGCTAC and AGATTGGGCCGCCTGGTGGTTCGGGGAGTCCCACTTT-GACTAC).
DNA ampl@cafion. Heavy-chain Ig gene-rearrangement products were amplified using genomic DNA ( 1 pg) in the presence of
mixed oligonucleotide primers (ACACGGC[C/T][G/C]TGTATT-
ACTGT) (FR3A) designed on consensus sequences for codons 89 through 95 (third framework region) of human Ig/heavychain variable region (VH): ' and a universal JH oligonucleotide primer 33). Oligonucleotides were synthesized by the solid-phase triester method. Both oligonucleotide primers are equipped with Clu I and EcoRI restriction sites, and a Kpn I and Hind111 restriction site, respectively, enabling cloning and sequence determination of the PCR-amplified fragments. DNA was amplified in the presence of 250 pmol deoxynucleotide triphosphates (dNTPs), 50 mmol KCI, IO mmol Tris-HCI pH 8, 1 mmol MgClz, 1% gelatin, 20 pmol of each oligonucleotide and 2.5 U of Taq DNA polymerase. The mixture was overlayered with mineral oil and subjected to one cycle of l minute at 94"C, 3 minutes at 52"C, 40 minutes at 72"C, followed by 40 cycles of 1 minute at 94°C 2 minutes, 30 seconds at 56% 90 seconds at 72"C, followed by a final extension of 7 minutes at 72°C performed on an automated heat block (DNA Thermal-Cycler, Perkin-Elmer Cetus). In all experiments, samples of genomic DNAs from monoclonal neoplastic B cells, normal reactive lymph nodes, tonsils, and T-cell leukemias were included as positive and negative controls. In addition, mixtures without template were included as a negative control. PCR products were size fractionated on alkaline , and 9; 62'C for p53 exon 7; 58°C for p53 exon 8), and extension (72°C) were done on an automated heat block. The reaction mixture (2 pL) was diluted 1:25 in 0.1% SDS, 10 mmol EDTA and further mixed I: 1 with a sequencing stop solution, containing 20 mmol NaOH. Samples were heated at 95'C for 5 minutes, chilled on ice, and immediately loaded onto a 6% acrylamide-0.08 mol/L TRIS-borate, 0.089 mol/L boric acid, 0.002 mol/L EDTA (TBE) gel containing 10% glycerol. Gels were run at 4 to 8 W for 14 to 16 hours at room temperature. The gels were fixed in 10% acetic acid, air dried and autoradiography was performed at -70°C with an intensifying screen for 6 to 24 hours. Cloning and sequencing of PCR products. PCR products were cloned in the pCR 1,OOO vector using the TA cloning system (Invitrogen Corp, San Diego, CA), following the manufacturer's instructions. DNA sequencing was performed directly from a small-scale plasmid preparation4' after determining the presence of an insert. The Sequenase version 2.0 (US Biochemical, Cleveland, OH) sys tern was used according to the manufacturer's instructions. DNA sequences were analyzed with the assistance of Mec-Vector version 3.5 software.
, S-GTGTTGTCTCCTAGGTTGGC

RESULTS
Clinical, morphologic, and immunophenotypic characterization. The clinical data of the six patients are presented in Table 1 and the results of immunophenotypic analysis of the CLL/SLL and DLL samples obtained from these six patients are summarized in Table 2 . The CLL/SLLs and DLLs in all six patients expressed a B-cell phenotype (CD20+, HLA-DR', Ig'). The Ig light chain isotypes of the CLL/SLL and DLL components were identical in five of the six cases. In the sixth case (case I), the SLL expressed K light chains and the subsequent DLL expressed X light chains. All 1365 six pairs of samples expressed IgM. In addition, the CLL in case 3 and both the CLL and the DLL in case 4 expressed IgD as well. Both the CLL/SLL and the DLL samples in three patients (cases 2,3, and 6) expressed CD5. In the other three patients (cases 1,4, and 5) the neoplastic B-cell populations were CDY. In case 3, the high proportion (73%) of CD20' CLL cells contrasted with 15% CD20' DLL cells. In case 5, the low percentage ( 1 1%) of CD20' SLL cells contrasted with 80% CD2Ot DLL cells. The proportion of CD20' CLL/SLL and DLL cells were comparably high (67% to 96%) in the other four cases.
Southern blot analysis of Ig and T-cell receptor gene rearrangements. The CLL/SLL and DLL samples of the six Richter's syndrome patients were evaluated in parallel. The results of Southern blot analysis of the various restriction endonuclease-digested DNA samples for antigen-receptor gene rearrangements are depicted in Table 3 and illustrated in Figs 1 and 2. Clonal rearrangement of the Ig-heavy-chain gene was detected in all six pairs of DNA samples. The molecular size of the rearranged JH locus of the CLL/SLL and DLL components was identical in four cases and was different in two cases (Fig 1) . Five of the six cases had more than one restriction-band fragment indicating rearrangement of both alleles. Analysis of the K light chain gene in BamHI-digested DNAs showed clonal rearrangement in the CLL/SLL and DLL samples of four cases and in the SLL sample of one case (case 1). In the group of four cases where both samples were rearranged, the Southern blot patterns were identical in three cases and different in one case (case 2 ) (Fig I , top) . Clonal rearrangement of the X light chain gene was detected in both the CLL and DLL samples in one case (case 6) and in the DLL sample of one case (case 1) (Fig 1, bottom) . The 8-kb CA germline bands were missing because of restriction fragment length polymorphism in case L 3 ' In summary, Southern blot analysis showed an identical Ig gene-rearrangement pattern in the CLL/SLL and DLL components in four cases and a different Ig gene-rearrangement pattern in the CLL/SLL and DLL components in two cases. The Tcell receptor B chain gene was present in the gemline configuration in all the samples from all six patients (Table 3) .
PCR amplification, cloning, and sequencing of the CDR3 region of the Ig-heavy chain gene. Cloning and sequencing studies were performed to determine whether differences in the Southern blot pattern of Ig gene rearrangement were the result of two different clones or somatic mutations. The two Richter's syndrome cases where the CLL/SLL and the DLL components have different patterns of clonal Ig gene rearrangement, and one of the cases where they have identical patterns of clonal Ig gene rearrangement were selected for cloning and sequencing the CDR3 region of the Ig heavy chain gene. PCR amplification of the six samples from the three cases resulted in PCR products ranging in size between 120 and 75 bp. The physical maps and nucleotide sequences of the Ig-heavy chain CDR3 region isolated from the CLL/ SLLs and DLLs of these three cases are illustrated in ulations with 63-and 42-bp long DNA sequences. The CDR3 region of the DLL sample from the same case consisted of 30 bp. Homologous CDR3 sequences were not detected in the SLL and DLL samples of case l . Case 2 contained two clones in the CLL and two clones in the DLL that were identical. Somatic point mutations or deletions were not detected. The sequencing data of the CLL and DLL samples of case 3 showed identical clones. CDR3-specific oligonucleotide hybridization oj' the JHprobed Southern blot. In case 2, the rehybridization of the JH-probed EcoRI-digested nitrocellulose filter with synthetic oligonucleotides specific for CDR3 showed a hybridization band at the site ofthe rearranged JH band in the CLL sample but not in the DLL sample (data not shown).
EBVanalysis. The six DNA samples were digested with the BamHI restriction endonuclease and subjected to Southern blot hybridization using a DNA probe specific for the fused termini of the EBV genome. A lymphoid cell line derived by EBV infection of normal polyclonal B cells and an EBVC clonal B-cell lymphoma line were used as controls for polymorphic and monomorphic EBV termini, respectively. The DLL sample from case 2 displayed a single intense positive band analogous to the monoclonal control (data not shown). None of the remaining CLL/SLL or DLL specimens contained evidence of EBV infection.
Proto-oncogene and tumor-suppressor gene analysis. The results of Southern blot and SSCP analysis of the c-myc, hcl-l, and bcl-2 proto-oncogenes and the Rb and p53 tumor-suppressor genes are presented in Table 4 . Southern blot analysis showed the germline configuration of the bcl-1, bcl-2, c-myc, and Rb genes (not shown). PCR-SSCP anal ysis of the p53 gene showed three abnormally migratin! bands: in exon 5 in the DLL sample of case 1, and in exon I in both the CLL and DLL samples of case 4 (Fig 4) . Thc nature of the p53 gene mutations detected by SSCP analysi: were further studied by cloning and sequencing of the PCR amplified exons. The DLL in case l had a G to T transitior in the second nucleotide of codon 176 resulting in a changc in the encoded amino acid from cysteine to phenylalaninc (Fig 5) . The CLL and DLL samples of case 4 contained thc identical point mutation, a C to T transition in the first nu cleotide of codon 282 leading to an alteration from argininc to tryptophane (Fig 3) . Southern blot analysis of Hinff-di gested DNA with 17 chromosome-specific pYNZ22. I anc p144-D6 probes showed only the mutated allele, implyini loss of the normal allele (not shown).
DISCUSSION
Human B-cell lymphomas are generally believed to rep resent monoclonal proliferations of neoplastic B cells tha originate from a single transformed lymphoid precursor.' The genetic defect of the parent cell is expressed in all o the members of the clone. However, the occasional biclona derivation and histologic transformation of B-cell lympho. mas indicates that additional genetic alterations of the neo, plastic clone or the development of a new and differen clone may occur.23.24*53 The majority of lymphomas that un. dergo transformation are low-grade follicular and diffua small lymphocytic lymphomas. The morphologic transfor, mation of CLL/SLL to DLL, which is usually associatec DLL components were identical. The discordant data of sequence and Southern blot analysis can be interpreted in different ways. One. the two neoplasms represent different clones and JH33 and/or FR3 primers do not recognize the Ig sequence of the DLL, but do amplify the CLL.s4 Alternatively, the DLL developed from the CLL, and represent the same clones, and somatic mutations that modified the restriction sites lie outside of the sequenced CDR3 regions.
To exclude one or the other possibility, the JH-probed ni--G trocellulose filter was rehybridized with case-specific CDR3 synthetic oligonucleotides. Because only the CLL DNA sample showed hybridization with the CDR3 probes, the nonidentical JH-rearranged band of the DLL sample represents a new clone that was not amplified by the FR4-JH33 PCR. However, further data concerning the clonal relationship in this case is provided by the results of EBV-DNA analysis. The integration of EBV genome in the DLL with clinical progression, has been designated Richter's syndrome. Two issues must be resolved in order to understand the development of Richter's syndrome: the clonal origin of the DLL and the secondary biologic effects on the CLL/SLL that are responsible for transformation.
There are two possible explanations for the occurrence of two histologically different lymphomas in the same patient. First, the neoplastic cell populations may represent two different clones as a result of different transforming events. Several reports describe cases of Richter's syndrome in which the CLL and the DLL express different Ig isotype^.^^.^'.'^ In addition, Southern blot analysis of Ig gene rearrangements has not shown concordant rearrangement bands in the CLL and DLL components of individual cases of Richter's syndrome.'8.20According to these reports, Richter's syndrome may be biclonal. However, in the transformation of follicular lymphoma the altered DNA sequences are the result ofsomatic mutation^.^^ Because somatic mutations change restriction-enzyme sites, the discordant Southern blot analyses do not necessarily indicate unrelated clonal development. In the present study, Southern blot analyses of Ig gene rearrangements showed discordant bands in two cases (cases 1 and 2). We performed PCR amplification, cloning, and sequencing of the CDR3 region of the Ig-heavy chain gene to determine whether somatic mutations or the development of a new clone is responsible for these different Ig gene-rearrangement patterns on the Southern blot. Two different CDR3 sequences were found in the SLL sample from case 1 indicating rearrangement of both alleles. Because the CDR3 sequence of the DLL sample from case I did not match any of the SLL sequences, may occur before or after the morphologic transformation of CLL. If the infection is a posttransformation event, the jntegrated EBV termini should show a polymorphic pattern on Southern blotting. If EBV infected the parent cell before expansion of the tumor cell population, the Southern blot will show a monomorphic pattern.55 Southern blot analysis showed a monomorphic pattern in this case, suggesting that this clonal expansion derived from a progenitor B cell which was already infected by EBV. Meanwhile, the CLL sample from case 2 was EBV-. Therefore, the CLL and DLL cells do not apparently represent the same clone in this instance.
The other model for the development of Richter's syndrome proposes that the two neoplasms are identical B-cell CLL-S 2. CLL-3 2.
CLL-8 2. CLL-9 ACACGCCTGTGTATTACTCTGCGAG L " L " L C . " " " " " . " " " """"""""".""" """"""."" """".
"""-ccc""^^-"~'~-~" ACACGGCTGTCTATTACTGTGCGAG """""""""""."
""""c"""""""~~ ""^~.^"^"^^^^^^^^^^..
"^^^^^^^^~^^^^^^"^^^^^. Though somatic point mutations of the CDR3 region were not detected in our cases, other segments could be mutated. Based on sequencing data of CLL cases, the frequency and sites of somatic mutations are not obvious. Lack of somatic mutations,6' random distribution of somatic m u t a t i o n~, 6~.~~ and selective CDR I mutation of the VH region6" have been reported as well. The molecular genetic analysis of our six cases of Richter's syndrome in conjunction with other analyses of individual cases indicates that the histologic transformation ofCLL to DLL does not occur in a single homogenous manner. Apparently, the DLL in Richter's syndrome may represent either a clonal progression of the original CLL or a second lymphoid malignancy. We investigated the involvement of several proto-oncogenes and tumor-suppressor genes in the progression of CLL to DLL using Southern blot and SSCP analysis. We studied loci that are known to be involved in B-cell malignanphoma p r o g r e s s i~n .~~. *~.~~
The examination of large numbers of CLLs has shown no or only rare cases containing bcl-l, bcl-2, or c-myc rearrangement?5.26@ Some DLLs have been found to be bcl-1 or bcl-2 rearrangedt9 and Ince Cies28,29.65-67 and are suspected of playing a role in lym- The p53 gene is one of the tumor-suppressor genes that may be involved in negative regulation of cell proliferat i~n .~" '~ Several lines of evidence support the notion that loss, alteration, or inactivation of this gene contributes to the development and progression of human malignancies.'* Gaidano et a129 investigated the frequency ofp53 mutations in a large series of B-cell malignancies and found histologically transformed cases of CLL (Richter's syndrome) to be frequently mutated. Ichikawa et aI3'described p53 gene mutations in a large series ofclinically advanced B-cell lymphomas. However, neither of the two studies analyzed the tumor cell populations from the same patients both before and after transformation. We performed SSCP and sequence analysis of exons 5 through 9 of the p53 gene in six paired .. .
samples of CLL and the subsequent DLL in order to determine the possible role of the p53 gene in tumor progression and transformation. We detected mutations in exon 5 (codon 176) of the DLL in case l and in exon 8 (codon 282) of both the CLL and the DLL in case 4. The exon 8 mutations in the CLL and DLL were identical. We did not detect p53 gene mutations in the other four cases of Richter's syndrome. It is obvious that p53 mutation was not primarily responsible for morphologic transformation in case 4, because the identical p53 mutation was present both before and after histologic transformation in both the CLL and DLL. In case I , the CLL and DLL clones were different and only the DLL cells were p53 mutated. Therefore, the p53 mutation may have played a role in the development of a new clone rather than in the morphologic transformation of the CLL/SLL in this case. This study addressed the issue of the clonal relationship between CLL and the subsequent DLL in Richter's syndrome, and sought to identify the factors responsible for transformation. We showed that the DLL may represent either the identical clone as the CLL/SLL, or may represent a new unrelated clone, and that none of the well-known oncogenes and tumor-suppressor genes are responsible for the transformation of CLL/SLL to DLL. Because the DLL may develop from the original CLL/SLL or may represent a different malignant clone, the transforming events involved in the development of Richter's syndrome may be different as well. In those cases of Richter's syndrome where the CLL and DLL represent the same clones, random or antigendriven somatic mutations may be involved in the progression of the lymphoma. In the development of biclonal Richter's syndrome, a genetic malformation that has no effect on the CLL cells, such as p53 gene mutation, may initiate the second malignancy. 
